Last reviewed · How we verify
MESA
At a glance
| Generic name | MESA |
|---|---|
| Sponsor | Meda Pharms |
| Target | Arachidonate 5-lipoxygenase, Peroxisome proliferator-activated receptor gamma, Prostaglandin G/H synthase 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Chronic ulcerative proctitis
- Chronic ulcerative rectosigmoiditis
- Ulcerative colitis
- Ulcerative colitis in remission
Common side effects
- Gas/Flatulence
- Flu
- Fever
- Leg/Joint pain
- Hemorrhoids
- Rectal pain
- Hair loss
Serious adverse events
- Hepatic failure
- Severe cutaneous adverse reactions
- Hypersensitivity reactions
- Renal impairment
- Mesalamine-induced acute intolerance syndrome
- Photosensitivity
- Nephrolithiasis
- Myocarditis
- Pericarditis
- Pancreatitis
Key clinical trials
- CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users
- Multi-Ethnic Study of Atherosclerosis (MESA)
- Active Mammography and Counseling (NA)
- 11C-PIB PET Study in MESA at Columbia University
- Assessment of Continuous Positive Airway Pressure Therapy in OSA and ILD (NA)
- Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary
- Individualized Response to Vitamin D Treatment Study (NA)
- 3-D Correction of Adolescent Idiopathic Scoliosis (AIS) With Differential Metals (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |